Patents Assigned to Gavish-Galilee Bio Applications Ltd.
  • Patent number: 10273169
    Abstract: A method for pretreatment of wastewater or recreational water with substantial reduction of total suspended solids and turbidity in a very short time is provided comprising treatment with nanocomposites and a bridging agent.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: April 30, 2019
    Assignee: GAVISH-GALILEE BIO APPLICATIONS, LTD.
    Inventor: Giora Rytwo
  • Patent number: 10188741
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 29, 2019
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Patent number: 9546102
    Abstract: A single step pretreatment of wastewater or recreational water is provided comprising treatment with nanocomposites consisting of an anchoring particle such as a clay mineral and one or more polymers.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: January 17, 2017
    Assignee: GAVISH-GALILEE BIO APPLICATIONS LTD.
    Inventor: Giora Rytwo
  • Patent number: 9358307
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: January 25, 2009
    Date of Patent: June 7, 2016
    Assignees: GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Publication number: 20160120977
    Abstract: A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.
    Type: Application
    Filed: November 4, 2015
    Publication date: May 5, 2016
    Applicant: GAVISH-GALILEE BIO APPLICATIONS, LTD.
    Inventors: Jacob Pitcovski, Jacob Vaya, Soliman Khatib, Elina Aizenshtein, Tal Gefen
  • Publication number: 20140042100
    Abstract: A single step pretreatment of wastewater or recreational water is provided comprising treatment with nanocomposites consisting of an anchoring particle such as a clay mineral and one or more polymers.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 13, 2014
    Applicant: Gavish-Galilee Bio Applications, Ltd.
    Inventor: Giora RYTWO
  • Publication number: 20120208879
    Abstract: Pharmaceutical or cosmetic compositions including cruciferous plant extract or isothiocyanates such as 4-methyl-thio-butyl-isothiocyanate which are useful for treating psoriasis are provided.
    Type: Application
    Filed: March 15, 2012
    Publication date: August 16, 2012
    Applicants: Gavish-Galilee Bio Applications Ltd., S.U.L.V.E. Ltd.
    Inventors: Ihab Sussan, Habib Sussan
  • Publication number: 20120156227
    Abstract: A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination
    Type: Application
    Filed: June 6, 2010
    Publication date: June 21, 2012
    Applicant: GAVISH-GALILEE BIO APPLICATIONS LTD.
    Inventors: Jacob Pitcovski, Jacob Vaya, Soliman Khatib, Alina Aizenshtein, Tal Gefen
  • Patent number: 8158161
    Abstract: Pharmaceutical or cosmetic compositions including cruciferous plant extract or isothiocyanates such as 4-methyl-thio-butyl-isothiocyanate which are useful for treating psoriasis are provided.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: April 17, 2012
    Assignees: S.U.L.V.E. Ltd., Gavish-Galilee Bio Applications Ltd.
    Inventors: Ihab Sussan, Habib Sussan
  • Patent number: 7892581
    Abstract: Methods and compositions comprising essential oils or components thereof for protecting harvested fruits against decay caused by a specific pathogenic fungus are provided, such as Cinnamon cassia oil for protection of persimmons against Alternaria alternata, strawberries against Botrytis cinerea, or mandarins against Penicillium italicum or Penicillium digitatum.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: February 22, 2011
    Assignee: Gavish-Galilee Bio Applications Ltd.
    Inventors: Emma Kvitnitsky, Ruth Ben-Arie, Irina Paluy, Olga Semenenko
  • Publication number: 20080286312
    Abstract: The invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a ?2-microglobulin molecule that is linked through its carboxyl terminal to a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a polypeptide stretch consisting of the full or partial transmembrane and/or cytoplasmic domains selected from the group consisting of a toll-like receptor (TLR) polypeptide, a CD40 polypeptide, and TLR and CD40 polypeptides fused in tandem, that allows the anchorage of the ?2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising an MHC class I epitope, wherein said antigenic peptide is preferably derived from a tumor-associated antigen or from a pathogenic antigen.
    Type: Application
    Filed: October 3, 2006
    Publication date: November 20, 2008
    Applicant: Gavish-Galilee Bio Applications Ltd.
    Inventors: Gideon Gross, Alon Margalit
  • Publication number: 20080213237
    Abstract: The invention relates to a method for the isolation of T cell lymphocyte, preferably, CD8+ cytotoxic T lymphocyte, which is capable of specifically recognizing an antigen related to a pathologic disorder. The method of the invention is base on ability of the CTL's to capture membrane from labeled target cells. The invention further provides compositions comprising said specific lymphocytes and methods for the treatment of said pathologic disorder using the specific lymphocytes isolated and prepared by the method of the invention.
    Type: Application
    Filed: March 9, 2006
    Publication date: September 4, 2008
    Applicants: Hadasit Medical Research Services and Development Ltd., Gavish Galilee Bio Applications Ltd.
    Inventors: Shoshana Frankenburg, Jacob Pitcovski, Tamar Peretz, Michal Lotem, Arthur Machlenkin, Ronny Uzana
  • Publication number: 20080044497
    Abstract: Pharmaceutical or cosmetic compositions including cruciferous plant extract or isothiocyanates such as 4-methyl-thio-butyl-isothiocyanate which are useful for treating psoriasis are provided.
    Type: Application
    Filed: January 12, 2006
    Publication date: February 21, 2008
    Applicants: S.U.L.V.E. Ltd., Gavish- Galilee Bio Applications Ltd.
    Inventors: Ihab Sussan, Habib Sussan
  • Patent number: 7323338
    Abstract: A method of increasing methionine and/or methionine related metabolites in a plant is provided. The method is effected by expressing within the plant a cystathionine ?-synthase encoded by a polynucleotide mutated in, or lacking, a region encoding an N-terminal portion of said cystathionine ?-synthase, said region being functional in downregulating an activity of said cystathionine ?-synthase in the plant.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: January 29, 2008
    Assignee: Gavish-Galilee Bio Applications Ltd.
    Inventor: Rachel Amir
  • Publication number: 20080019996
    Abstract: The invention relates to a method for treatment of chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), prostate cancer and ?-globin disorders such as sickle cell anemia and ?-thalassemia, comprising administration of a mycelium extract from at least one higher Basidiomycetes medicinal mushroom selected from the group consisting of Ganoderma adspersum, Hypsizygus ulmarium, Kuehneromyces mutabilis, Omphalotus olearius, Panus conchatus, Piptoporus betulinus, Pleurotus eryngii, and Trametes zonata.
    Type: Application
    Filed: August 20, 2007
    Publication date: January 24, 2008
    Applicants: Gavish-Galilee Bio Applications Ltd., Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Jamal MAHAJNA, Majed YASSIN, Solomon WASSER
  • Patent number: 7319143
    Abstract: The invention provides DNA molecules encoding a chimeric polypeptide comprising (a) a component of a MHC molecule capable of association on a cell surface with an endogenous MHC molecule component of the same class, and (b) an intracellular region of a signal transduction element capable of activating T cells. Component (a) may be a monomorphic component and is preferably beta 2-microglobulin, or a polymorphic class I or class II component. The signal transduction element (b) capable of activating T cells may be a component of T-cell receptor CD3, preferably the CD3 zeta (zeta) polypeptide, a B cell receptor polypeptide or an Fc receptor polypeptide. Immune cells such as a CTLs expressing said chimeric MHC molecules specifically eliminate or inactivate harmful T cells and are useful for treating graft rejection and autoimmune diseases.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: January 15, 2008
    Assignee: Gavish-Galilee Bio Application Ltd.
    Inventors: Gideon Gross, Alon Margalit
  • Publication number: 20060246095
    Abstract: Disclosed are recombinant multiple epitope polypeptides (MEPs) consisting of T cell epitopes derived from tumor-associated antigens capable of being presented by an antigen presenting cell (APC), the recombinant nucleic acid sequences and expression vectors encoding them, and host cells transfected with said expression vectors. Further described are LTB-MEP fusion proteins comprising the E. Coli heat labile enterotoxin subunit B (LTB) peptide fused to a MEP by a synthetic linker, the recombinant nucleic acid sequences and expression vectors encoding them and host cell transfected with said expression vectors. Further included are compositions for inducing an immune response against malignancies, pharmaceutical compositions and a transdermal drug delivery system for the treatment of malignant disorders. Also disclosed are methods for conferring immunity against malignancies and for the treatment of malignant disorders.
    Type: Application
    Filed: March 24, 2006
    Publication date: November 2, 2006
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, GAVISH-GALILEE-BIO APPLICATIONS LTD.
    Inventors: Tamar Peretz, Michal Lotem, Shoshana Frankenburg, Jacob Pitcovski, Adva Levi, Hanah Margalit, Yael Altuvia
  • Publication number: 20060057157
    Abstract: The invention relates to a method for treatment of chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), prostate cancer and ?-globin disorders such as sickle cell anemia and ?-thalassemia, comprising administration of a mycelium extract from at least one higher Basidiomycetes medicinal mushroom selected from the group consisting of Ganoderma adspersum, Hypsizygus ulmarium, Kuehneromyces mutabilis, Omphalotus olearius, Panus conchatus, Piptoporus betulinus, Pleurotus eryngii, and Trametes zonata.
    Type: Application
    Filed: October 25, 2005
    Publication date: March 16, 2006
    Applicants: Gavish-Galilee Bio Applications Ltd., Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Jamal Mahajna, Majed Yassin, Solomon Wasser
  • Publication number: 20060045887
    Abstract: The invention relates to compositions comprising a mycelium extract from at least one higher Basidiomycetes medicinal mushroom selected from the group consisting of Ganoderma adspersum, Hypsizygus ulmarium, Kuehneromyces mutabilis, Omphalotus olearius, Panus conchatus, Piptoporus betulinus, Pleurotus eryngii, and Trametes zonata, said composition having selective antiproliferative activity on the human chronic myelogenous leukemia K562 cells and on the human prostate cancer LNCaP cells. The compositions are useful for treatment of chronic myelogenous leukemia (CML), Ph+ acute lymphoblastic leukemia (ALL), prostate cancer and ?-globin disorders such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: August 25, 2004
    Publication date: March 2, 2006
    Applicants: Gavish-Galilee Bio Applications Ltd., Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Jamal Mahajna, Majed Yassin, Solomon Wasser
  • Publication number: 20060003315
    Abstract: The invention provides a polynucleotide comprising a sequence encoding a polypeptide comprising a beta2-microglobulin molecule linked through its carboxyl terminal to a polypeptide stretch that allows the anchorage of the beta2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising a MHC class I epitope, wherein said antigenic peptide is not related to an autoimmune disease and is preferably derived from a tumor-associated antigen or from a pathogenic antigen. Antigen presenting cells, and DNA and cellular vaccines for treatment of cancer and infectious diseases, are also provided.
    Type: Application
    Filed: June 12, 2003
    Publication date: January 5, 2006
    Applicant: Gavish-Galilee Bio Applications Ltd.
    Inventors: Gideon Gross, Alon Margalit